Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Vivos Therapeutics (VVOS) over the last 4 years, with Q3 2025 value amounting to -$679000.0.

  • Vivos Therapeutics' Non Operating Income fell 367222.22% to -$679000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$914000.0, marking a year-over-year decrease of 156181.82%. This contributed to the annual value of -$110000.0 for FY2024, which is 4811.32% up from last year.
  • Per Vivos Therapeutics' latest filing, its Non Operating Income stood at -$679000.0 for Q3 2025, which was down 367222.22% from -$163000.0 recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Non Operating Income registered a high of $51000.0 during Q1 2023, and its lowest value of -$679000.0 during Q3 2025.
  • Its 4-year average for Non Operating Income is -$89666.7, with a median of -$37000.0 in 2022.
  • As far as peak fluctuations go, Vivos Therapeutics' Non Operating Income surged by 23421.05% in 2023, and later crashed by 367222.22% in 2025.
  • Vivos Therapeutics' Non Operating Income (Quarter) stood at -$38000.0 in 2022, then skyrocketed by 63.16% to -$14000.0 in 2023, then tumbled by 385.71% to -$68000.0 in 2024, then plummeted by 898.53% to -$679000.0 in 2025.
  • Its last three reported values are -$679000.0 in Q3 2025, -$163000.0 for Q2 2025, and -$4000.0 during Q1 2025.